An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps

Trial Identifier: LTS18420
Sponsor: Sanofi
Collaborator:
Regeneron Pharmaceuticals
Start Date: March 2026
Primary Completion Date: December 2028
Study Completion Date: December 2028
Condition: Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, Western Australia Spearwood, Western Australia, AUSTRALIA, 6163
CANADA, Quebec Québec City, Quebec, CANADA, G1V 4G5
CANADA, Quebec Québec City, Quebec, CANADA, G1V 4W2
CANADA, Quebec Québec City, Quebec, CANADA, G2J 0C4
CHILE, Biobío Concepción, Biobío, CHILE, 4070094
CHILE, Maule Talca, Maule, CHILE, 3465584
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 7500692
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 7500505
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 8207257
CHINA Baotou, CHINA, 014040
CHINA Beijing, CHINA, 100730
CHINA Chengdu, CHINA, 610017
CHINA Jingzhou, CHINA, 434020
CHINA Shenyang, CHINA, 110004
CHINA Taiyuan, CHINA, 030001
CZECHIA Prague, CZECHIA, 150 06
HUNGARY Budapest, HUNGARY, 1046
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 07061
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 03080
UNITED KINGDOM, Bradford Bradford, UNITED KINGDOM, BD9 6RJ
UNITED KINGDOM, Lancashire Wigan, Lancashire, UNITED KINGDOM, Wn6 9ep
UNITED STATES, California La Mesa, California, UNITED STATES, 91942
UNITED STATES, Oklahoma Oklahoma City, Oklahoma, UNITED STATES, 73120